Arthritis therapy helps patients for up to 3 years
Arthritis therapy helps patients for up to 3 years
Earlier use of second-line agents in patients with rheumatoid arthritis (RA) can have lasting positive effects, according to a study from Montreal General Hospital presented at a recent meeting of the American College of Rheumatologists.
Patients with early RA (two years or less) who did not respond to first-line nonsteroidal anti-inflammatory drugs were given second-line therapy with Plaquenil (hydroxycloroquine sulfate) for nine months. They experienced a significant reduction in the average pain intensity, and the impact on their general well-being continued for as long as three years. The control group received comparable second-line therapy after the nine-month trial but did not see the same benefit to pain reduction and well-being.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.